What CFOs Need To Do To Save Their 340B Program

The 340B Drug Discount Program has enabled healthcare providers to expand treatments and access to underserved populations for several decades. But, in recent years, the complexity and increasing rate of change in the program’s compliance requirements is causing long-time program participants to reconsider their participation in the program.  Fear of the financial risks associated with audit failure or an unexpected manufacturer payback, and uncertainty over what will be required to maintain compliance can overwhelm financial decision-making. 

In this white paper, hospital leaders and 340B industry experts share their perspectives on what CFOs can do to demonstrate that they are good program stewards, prepare for additional reporting requirements, and protect their program.